Shares in Callan JMB (CJMB), the Texas-based integrated logistics and fulfillment company, shot through the roof on Thursday after it teamed up with biopharma firm Attune Biotech. CJMB surged 260.71% as of 1:37 p.m. EST.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In a statement, the logistics company noted that it will serve as an independent third-party supervisor for Attune’s drug production, quality systems, and product rollout activities.
Callan JMB noted that it expects the partnership to generate between $50 million and $75 million in combined revenue over the next five years. The firm will take between 50% and 60% of the revenue.
Callan Looks to Generate Up to $45M from New Deal
As a clinical-stage biopharmaceutical company, Biostax, the corporation behind Attune Biotech, is currently testing several treatments, with some already at the commercial stage.
Its pipeline includes Lodonal (JKB-122), an immune system restoration drug still under development; Menk-201, an experimental treatment aimed at patients with failing immune systems; and Cytocide-100, an acidic liquid designed to kill bacteria, viruses, fungi, and other harmful germs.
“This [deal] represents an approximate potential revenue opportunity of $25 million to $45 million for Callan JMB over the next 5 years,” said Wayne Williams, Callan’s founder and chief executive. Williams added that the collaboration will help Attune meet the strict standards required by the U.S. government for purchase contracts.
Callan to Speed Up Deployment Timeline for Attune Biotech
Explaining its readiness for the deal, Callan JMB noted that it has over 20 years of experience working with U.S. agencies and centers such as the Biomedical Advanced Research and Development Authority, the Strategic National Stockpile, and the Department of Defense, to manage “national stockpile assets” through its Coldchain Technology Services subsidiary.
These assets refer to products such as drugs, vaccines, antidotes, and personal protective equipment locked in secret and secure warehouses by the government for use during periods of crisis.
“Callan JMB brings immediate deployment capability through existing federal infrastructure, bypassing the typical 27-48 month logistics setup timeline for new pharmaceutical products,” Callan JMB noted.
Is CJMB Stock a Buy or Sell?
TipRanks’ AI analysts, using models from Gemini, xAI, Perplexity, OpenAI, and DeepSeek, mostly rate Callan JMB shares as Neutral, with Underperform as the next most common view.
For instance, OpenAI-5.2 rates the stock a Neutral, with a score of 43 out of 100, pointing to the firm’s “sharply deteriorated financial performance.” The AI analyst’s $1 price target implies about 76% downside risk from current levels.
